http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 NEWTON, Mass., November 12, 2009 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that... http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/0/4/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement http://pharmalicensing.com/redirs/news_rss//public/news/view/499902/0/4/novelos-therapeutics-closes-last-tranche-in-9-million-private-placement Basel, November 12, 2009 - Novartis announced the availability of Prevacid http://pharmalicensing.com/redirs/news_rss//public/news/view/499908/0/4/novartis-launches-prevacid http://pharmalicensing.com/redirs/news_rss//public/news/view/499908/0/4/novartis-launches-prevacid Milan (Italy), 11 November 2009 - MolMed S.p.A. (Milan:MLM) announces that the European Commission has granted Orphan Drug designation for MolMed's investigational new antitumour therapeutic drug... http://pharmalicensing.com/redirs/news_rss//public/news/view/499722/0/4/the-european-commission-grants-orphan-drug-designation-for-ngr-htnf-in-the-treatment-of-hepatocellular-carcinoma http://pharmalicensing.com/redirs/news_rss//public/news/view/499722/0/4/the-european-commission-grants-orphan-drug-designation-for-ngr-htnf-in-the-treatment-of-hepatocellular-carcinoma CAMBRIDGE, Mass. and TOKYO, Japan, November 10, 2009-- Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive... http://pharmalicensing.com/redirs/news_rss//public/news/view/499593/0/4/ironwood-and-astellas-announce-japan-licensing-agreement-for-linaclotide http://pharmalicensing.com/redirs/news_rss//public/news/view/499593/0/4/ironwood-and-astellas-announce-japan-licensing-agreement-for-linaclotide November 04, 2009 -- Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA. http://pharmalicensing.com/redirs/news_rss//public/news/view/498815/0/4/new-phase-iia-data-on-tmc435-in-patients-with-hepatitis-c-presented-at-the-ongoing-aasld-meeting http://pharmalicensing.com/redirs/news_rss//public/news/view/498815/0/4/new-phase-iia-data-on-tmc435-in-patients-with-hepatitis-c-presented-at-the-ongoing-aasld-meeting Strasbourg, France, November, 4th, 2009 - Transgene S.A. (Euronext Paris: FR0005175080) today announced the enrolment of the first patient in the Phase I trial of TG4023 (MVA-FCU1), its newest... http://pharmalicensing.com/redirs/news_rss//public/news/view/498840/0/4/transgene-first-patient-enrolled-in-phase-i-trial-of-tg4023-for-the-treatment-of-liver-tumours http://pharmalicensing.com/redirs/news_rss//public/news/view/498840/0/4/transgene-first-patient-enrolled-in-phase-i-trial-of-tg4023-for-the-treatment-of-liver-tumours CAMBRIDGE, Mass.-- November 3, 2009-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through... http://pharmalicensing.com/redirs/news_rss//public/news/view/498583/0/4/idera-pharmaceuticals-presents-preclinical-data-on-imo-2125-its-lead-drug-candidate-for-chronic-hepatitis-c-virus-infection-at-liver-meeting-2009 http://pharmalicensing.com/redirs/news_rss//public/news/view/498583/0/4/idera-pharmaceuticals-presents-preclinical-data-on-imo-2125-its-lead-drug-candidate-for-chronic-hepatitis-c-virus-infection-at-liver-meeting-2009 CAMBRIDGE, Mass., November 3, 2009 -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral... http://pharmalicensing.com/redirs/news_rss//public/news/view/498585/0/4/idenix-pharmaceuticals-initiates-phase-ii-clinical-trial-of-idx184-in-combination-with-pegylated-interferon-and-ribavirin-for-the-treatment-of-hepatitis-c-virus-hcv http://pharmalicensing.com/redirs/news_rss//public/news/view/498585/0/4/idenix-pharmaceuticals-initiates-phase-ii-clinical-trial-of-idx184-in-combination-with-pegylated-interferon-and-ribavirin-for-the-treatment-of-hepatitis-c-virus-hcv CAMBRIDGE, Mass. and New York, November 2, 2009 -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top line results from two Phase 3 clinical trials... http://pharmalicensing.com/redirs/news_rss//public/news/view/498536/0/4/ironwood-and-forest-announce-positive-linaclotide-results-from-two-pivotal-phase-3-trials-in-patients-with-chronic-constipation http://pharmalicensing.com/redirs/news_rss//public/news/view/498536/0/4/ironwood-and-forest-announce-positive-linaclotide-results-from-two-pivotal-phase-3-trials-in-patients-with-chronic-constipation RARITAN, N.J. (Oct. 23, 2009) - Ortho Clinical Diagnostics announced the launch of FETALSCREEN(TM) II Fetal Maternal Hemorrhage Screening Test, a simple, qualitative test that detects D (Rho)... http://pharmalicensing.com/redirs/news_rss//public/news/view/499817/0/4/ortho-clinical-diagnostics-launches-fetalscreen-tm-ii-fetal-maternal-hemorrhage-screening-test http://pharmalicensing.com/redirs/news_rss//public/news/view/499817/0/4/ortho-clinical-diagnostics-launches-fetalscreen-tm-ii-fetal-maternal-hemorrhage-screening-test